Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results.
暂无分享，去创建一个
D. Lake | C. Hudis | L. Norton | M. Theodoulou | M. Robson | H. Burstein | N. Tung | B. Overmoyer | T. Traina | B. Moy | I. Kuter | L. Schapira | S. Come | A. Seidman | E. Winer | Ching-Tung Chen | S. Modi | P. Ryan | M. Dickler | E. Mayer | J. Younger | L. Schnipper | T. Gilewski | C. Dang | G. D’Andrea | G. Wulf | S. Sugarman | M. Fornier | V. Currie | P. Drullinsky | S. Schumer | C. Zarwan | A. Partridge | T. Troso-Sandoval | S. Isakoff | N. Lin | J. Bromberg | M. Gorsky | Clifford A. Hudis | D. Atieh | SJ Isakoff